{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T23:21:58Z","timestamp":1788650518345,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"EJPRD","award":["825575"],"award-info":[{"award-number":["825575"]}]},{"name":"EJPRD","award":["825575"],"award-info":[{"award-number":["825575"]}]},{"name":"EJPRD","award":["825575"],"award-info":[{"award-number":["825575"]}]},{"name":"TreatHSP network","award":["01GM2209A"],"award-info":[{"award-number":["01GM2209A"]}]},{"name":"ERDERA","award":["101156595"],"award-info":[{"award-number":["101156595"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Res Methodol"],"DOI":"10.1186\/s12874-025-02626-x","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T06:59:38Z","timestamp":1753858778000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparing randomized trial designs to estimate treatment effect in rare diseases with longitudinal models: a simulation study showcased by Autosomal Recessive Cerebellar Ataxias using the SARA score"],"prefix":"10.1186","volume":"25","author":[{"given":"Niels","family":"Hendrickx","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"France","family":"Mentr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alzahra","family":"Hamdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats O.","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"Hooker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Trasch\u00fctz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Gagnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Sch\u00fcle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthis","family":"Synofzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Comets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ARCA Study Group, EVIDENCE-RND consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole Maria","family":"Heussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf-Dieter","family":"Hilgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Klockgether","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yevgen","family":"Ryeznik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleksandr","family":"Sverdlov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"2626_CR1","unstructured":"Research C for DE and. E9 Statistical Principles for Clinical Trials. FDA; 2020. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/e9-statistical-principles-clinical-trials. [cited 2024 Dec 18]."},{"key":"2626_CR2","unstructured":"Research C for DE and. Real-World Data: Assessing Registries To Support Regulatory Decision-Making for Drug and Biological Products. FDA; 2023. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/real-world-data-assessing-registries-support-regulatory-decision-making-drug-and-biological-products. [cited 2024 Dec 17]."},{"issue":"10","key":"2626_CR3","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1002\/sim.8913","volume":"40","author":"S Buatois","year":"2021","unstructured":"Buatois S, Ueckert S, Frey N, Retout S, Mentr\u00e9 F. cLRT-Mod: An efficient methodology for pharmacometric model-based analysis of longitudinal phase II dose finding studies under model uncertainty. Stat Med. 2021;40(10):2435\u201351.","journal-title":"Stat Med"},{"issue":"1","key":"2626_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2012.24","volume":"2","author":"KE Karlsson","year":"2013","unstructured":"Karlsson KE, Vong C, Bergstrand M, Jonsson EN, Karlsson MO. Comparisons of Analysis Methods for Proof-of-Concept Trials. CPT Pharmacometrics Syst Pharmacol. 2013;2(1): e23.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"4","key":"2626_CR5","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.neuron.2019.01.049","volume":"101","author":"M Synofzik","year":"2019","unstructured":"Synofzik M, Puccio H, Mochel F, Sch\u00f6ls L. Autosomal Recessive Cerebellar Ataxias: Paving the Way toward Targeted Molecular Therapies. Neuron. 2019;101(4):560\u201383.","journal-title":"Neuron"},{"issue":"2","key":"2626_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1089\/nat.2021.0039","volume":"32","author":"M Synofzik","year":"2022","unstructured":"Synofzik M, van Roon-Mom WMC, Marckmann G, van Duyvenvoorde HA, Graessner H, Sch\u00fcle R, et al. Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives. Nucleic Acid Ther. 2022;32(2):83\u201394.","journal-title":"Nucleic Acid Ther"},{"issue":"3","key":"2626_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1208\/s12248-024-00925-7","volume":"26","author":"N Hendrickx","year":"2024","unstructured":"Hendrickx N, Mentr\u00e9 F, Trasch\u00fctz A, Gagnon C, Sch\u00fcle R, Synofzik M, et al. Prediction of Individual Disease Progression Including Parameter Uncertainty in Rare Neurodegenerative Diseases: The Example of Autosomal-Recessive Spastic Ataxia Charlevoix Saguenay (ARSACS). AAPS J. 2024;26(3):57.","journal-title":"AAPS J"},{"key":"2626_CR8","doi-asserted-by":"publisher","unstructured":"Trasch\u00fctz A, Adarmes-G\u00f3mez AD, Anheim M, Baets J, Brais B, Gagnon C, et al. Responsiveness of the Scale for the Assessment and Rating of Ataxia and Natural History in 884 Recessive and Early Onset Ataxia Patients. Annals of Neurology.;n\/a(n\/a). Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/https:\/\/doi.org\/10.1002\/ana.26712. [cited 2023 Aug 28].","DOI":"10.1002\/ana.26712"},{"issue":"6","key":"2626_CR9","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1002\/mds.29397","volume":"38","author":"A Trasch\u00fctz","year":"2023","unstructured":"Trasch\u00fctz A, Adarmes-Gomez AD, Anheim M, Baets J, Falkenburger BH, Gburek-Augustat J, et al. Autosomal Recessive Cerebellar Ataxias in Europe: Frequency, Onset, and Severity in 677 Patients. Mov Disord. 2023;38(6):1109\u201312.","journal-title":"Mov Disord"},{"issue":"5","key":"2626_CR10","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1056\/NEJMoa2310151","volume":"390","author":"T Bremova-Ertl","year":"2024","unstructured":"Bremova-Ertl T, Ramaswami U, Brands M, Foltan T, Gautschi M, Gissen P, et al. Trial of N-Acetyl-l-Leucine in Niemann-Pick Disease Type C. N Engl J Med. 2024;390(5):421\u201331.","journal-title":"N Engl J Med"},{"issue":"3","key":"2626_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0119632","volume":"10","author":"H Liu-Seifert","year":"2015","unstructured":"Liu-Seifert H, Andersen SW, Lipkovich I, Holdridge KC, Siemers E. A Novel Approach to Delayed-Start Analyses for Demonstrating Disease-Modifying Effects in Alzheimer\u2019s Disease. PLoS ONE. 2015;10(3): e0119632.","journal-title":"PLoS ONE"},{"issue":"4","key":"2626_CR12","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/pst.1931","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang D, Robieson W, Zhao J, Wiener C, Koch G. Statistical considerations in a delayed-start design to demonstrate disease modification effect in neurodegenerative disorders. Pharm Stat. 2019;18(4):407\u201319.","journal-title":"Pharm Stat"},{"issue":"11","key":"2626_CR13","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1212\/01.wnl.0000219042.60538.92","volume":"66","author":"T Schmitz-H\u00fcbsch","year":"2006","unstructured":"Schmitz-H\u00fcbsch T, du Montcel ST, Baliko L, Berciano J, Boesch S, Depondt C, et al. Scale for the assessment and rating of ataxia: Development of a new clinical scale. Neurology. 2006;66(11):1717\u201320.","journal-title":"Neurology"},{"key":"2626_CR14","doi-asserted-by":"publisher","unstructured":"Hamdan A, Hendrickx N, Hooker AC, Chen X, Comets E, Trasch\u00fctz A, et al. Longitudinal Analysis of Natural History Progression of Rare and Ultra-Rare Cerebellar Ataxias Using Item Response Theory. Clinical Pharmacology & Therapeutics.;n\/a(n\/a). Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/https:\/\/doi.org\/10.1002\/cpt.3466. [cited 2024 Nov 6].","DOI":"10.1002\/cpt.3466"},{"key":"2626_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.677551","volume":"12","author":"A Trasch\u00fctz","year":"2021","unstructured":"Trasch\u00fctz A, Reich S, Adarmes AD, Anheim M, Ashrafi MR, Baets J, et al. The ARCA Registry: A Collaborative Global Platform for Advancing Trial Readiness in Autosomal Recessive Cerebellar Ataxias. Front Neurol. 2021;12: 677551.","journal-title":"Front Neurol"},{"issue":"1","key":"2626_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1750-1172-8-41","volume":"8","author":"M Synofzik","year":"2013","unstructured":"Synofzik M, Soehn AS, Gburek-Augustat J, Schicks J, Karle KN, Sch\u00fcle R, et al. Autosomal recessive spastic ataxia of Charlevoix Saguenay (ARSACS): expanding the genetic, clinical and imaging spectrum. Orphanet J Rare Dis. 2013;8(1):41.","journal-title":"Orphanet J Rare Dis"},{"key":"2626_CR17","unstructured":"Beal S, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM User\u2019s guides. (1989\u20132009). Ellicott City, MD, USA: Icon Development Solutions; 2009."},{"issue":"3","key":"2626_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit\u2013a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79(3):241\u201357.","journal-title":"Comput Methods Programs Biomed"},{"issue":"1","key":"2626_CR19","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1214\/aos\/1018031103","volume":"27","author":"B Delyon","year":"1999","unstructured":"Delyon B, Lavielle M, Moulines E. Convergence of a stochastic approximation version of the EM algorithm. Ann Stat. 1999;27(1):94\u2013128.","journal-title":"Ann Stat"},{"issue":"5","key":"2626_CR20","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s10928-007-9060-6","volume":"34","author":"Y Wang","year":"2007","unstructured":"Wang Y. Derivation of various NONMEM estimation methods. J Pharmacokinet Pharmacodyn. 2007;34(5):575\u201393.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2626_CR21","unstructured":"R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2022. Available from: https:\/\/www.R-project.org\/"},{"issue":"2","key":"2626_CR22","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/ije\/dym001","volume":"36","author":"DN Lathyris","year":"2007","unstructured":"Lathyris DN, Trikalinos TA, Ioannidis JP. Evidence from crossover trials: empirical evaluation and comparison against parallel arm trials. Int J Epidemiol. 2007;36(2):422\u201330.","journal-title":"Int J Epidemiol"},{"key":"2626_CR23","doi-asserted-by":"crossref","unstructured":"Fields T, Patterson M, Bremova-Ertl T, Belcher G, Billington I, Churchill GC, et al. A master protocol to investigate a novel therapy acetyl-l-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 gangliosidoses, and ataxia telangiectasia. Trials. 2021 Jan 22;22(1):84. [cited 2024 Nov 26].","DOI":"10.1186\/s13063-020-05009-3"},{"key":"2626_CR24","unstructured":"IntraBio Inc. Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study. clinicaltrials.gov; 2023 Sep. Report No.: NCT05163288. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05163288"},{"issue":"3","key":"2626_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264177","volume":"17","author":"E Petley","year":"2022","unstructured":"Petley E, Yule A, Alexander S, Ojha S, Whitehouse WP. The natural history of ataxia-telangiectasia (A-T): A systematic review. PLoS ONE. 2022;17(3): e0264177.","journal-title":"PLoS ONE"},{"key":"2626_CR26","unstructured":"IntraBio Inc. Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T): A Multinational, Multicenter, Open-label, Rater-blinded Phase II Study. clinicaltrials.gov; 2023 Aug. Report No.: NCT03759678. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03759678. [cited 2024 Nov 26]."},{"issue":"1","key":"2626_CR27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1177\/08830738211028394","volume":"37","author":"A Brueggemann","year":"2022","unstructured":"Brueggemann A, Bicvic A, Goeldlin M, Kalla R, Kerkeni H, Mantokoudis G, et al. Effects of Acetyl-DL-Leucine on Ataxia and Downbeat-Nystagmus in Six Patients With Ataxia Telangiectasia. J Child Neurol. 2022;37(1):20\u20137.","journal-title":"J Child Neurol"},{"key":"2626_CR28","unstructured":"Weill Medical College of Cornell University. Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich&#x27;s Ataxia. clinicaltrials.gov; 2024 Oct. Report No.: NCT05302271. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05302271. [cited 2024 Nov 26]."},{"key":"2626_CR29","unstructured":"Astellas Gene Therapies. A Multicenter, Open-Label, Dose Escalation, Phase 1b Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ASP2016 for Friedreich Ataxia Cardiomyopathy. clinicaltrials.gov; 2024 Nov. Report No.: NCT06483802. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06483802. [cited 2024 Nov 26]."},{"key":"2626_CR30","unstructured":"Lexeo Therapeutics. A Phase 1&#x2F;2 Study of the Safety and Efficacy of LX2006 Gene Therapy in Participants With Cardiomyopathy Associated With Friedreich&#x27;s Ataxia. clinicaltrials.gov; 2024 Nov. Report No.: NCT05445323. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05445323. [cited 2024 Nov 26]."},{"issue":"5","key":"2626_CR31","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/mds.28478","volume":"36","author":"M Grobe-Einsler","year":"2021","unstructured":"Grobe-Einsler M, Taheri Amin A, Faber J, Schaprian T, Jacobi H, Schmitz-H\u00fcbsch T, et al. Development of SARAhome, a New Video-Based Tool for the Assessment of Ataxia at Home. Mov Disord. 2021;36(5):1242\u20136.","journal-title":"Mov Disord"},{"key":"2626_CR32","doi-asserted-by":"crossref","unstructured":"Hamdan A, Hooker AC, Chen X, Trasch\u00fctz A, Sch\u00fcle R, Group AS, et al. Item performance of the scale for the assessment and rating of ataxia in rare and ultra-rare genetic ataxias. CPT: Pharmacometrics & Systems Pharmacology. 2024;13(8):1327\u201340.","DOI":"10.1002\/psp4.13162"},{"issue":"11","key":"2626_CR33","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1002\/mds.21544","volume":"22","author":"A Weyer","year":"2007","unstructured":"Weyer A, Abele M, Schmitz-H\u00fcbsch T, Schoch B, Frings M, Timmann D, et al. Reliability and validity of the scale for the assessment and rating of ataxia: a study in 64 ataxia patients. Mov Disord. 2007;22(11):1633\u20137.","journal-title":"Mov Disord"},{"issue":"5","key":"2626_CR34","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1007\/s12311-024-01700-2","volume":"23","author":"M Potashman","year":"2024","unstructured":"Potashman M, Rudell K, Pavisic I, Suminski N, Doma R, Heinrich M, et al. Content Validity of the Modified Functional Scale for the Assessment and Rating of Ataxia (f-SARA) Instrument in Spinocerebellar Ataxia. Cerebellum. 2024;23(5):2012\u201327.","journal-title":"Cerebellum"},{"issue":"5","key":"2626_CR35","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/acn3.52024","volume":"11","author":"D Hermle","year":"2024","unstructured":"Hermle D, Schubert R, Barallon P, Ilg W, Sch\u00fcle R, Reilmann R, et al. Multifeature quantitative motor assessment of upper limb ataxia including drawing and reaching. Annals of Clinical and Translational Neurology. 2024;11(5):1097.","journal-title":"Annals of Clinical and Translational Neurology"},{"issue":"11","key":"2626_CR36","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1002\/mds.29206","volume":"37","author":"W Ilg","year":"2022","unstructured":"Ilg W, M\u00fcller B, Faber J, van Gaalen J, Hengel H, Vogt IR, et al. Digital Gait Biomarkers Allow to Capture 1-Year Longitudinal Change in Spinocerebellar Ataxia Type 3. Mov Disord. 2022;37(11):2295\u2013301.","journal-title":"Mov Disord"},{"issue":"1","key":"2626_CR37","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s12311-021-01257-4","volume":"21","author":"H Donath","year":"2021","unstructured":"Donath H, Woelke S, Schubert R, Kieslich M, Theis M, Auburger G, et al. Neurofilament Light Chain Is a Biomarker of Neurodegeneration in Ataxia Telangiectasia. Cerebellum (London, England). 2021;21(1):39.","journal-title":"Cerebellum (London, England)"},{"issue":"1","key":"2626_CR38","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13024-019-0338-0","volume":"14","author":"QF Li","year":"2019","unstructured":"Li QF, Dong Y, Yang L, Xie JJ, Ma Y, Du YC, et al. Neurofilament light chain is a promising serum biomarker in spinocerebellar ataxia type 3. Mol Neurodegener. 2019;14(1):39.","journal-title":"Mol Neurodegener"},{"key":"2626_CR39","unstructured":"The University of Queensland. Single Arm Open-label Clinical Trial in Ataxia-telangiectasia to Test the Effects of Nicotinamide Riboside on Ataxia Scales, Immune Function, and Neurofilament Light Chain. clinicaltrials.gov; 2024 Apr. Report No.: NCT06324877. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06324877. [cited 2024 Nov 26]."},{"issue":"1","key":"2626_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/brain\/awab404","volume":"145","author":"M Benatar","year":"2022","unstructured":"Benatar M, Wuu J, McHutchison C, Postuma RB, Boeve BF, Petersen R, et al. Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases. Brain. 2022;145(1):27\u201344.","journal-title":"Brain"},{"issue":"18","key":"2626_CR41","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1002\/sim.10088","volume":"43","author":"M Philipp","year":"2024","unstructured":"Philipp M, Tessier A, Donnelly M, Fang L, Feng K, Zhao L, et al. Model-based bioequivalence approach for sparse pharmacokinetic bioequivalence studies: Model selection or model averaging? Stat Med. 2024;43(18):3403\u201316.","journal-title":"Stat Med"},{"issue":"3","key":"2626_CR42","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1208\/s12248-018-0205-x","volume":"20","author":"S Buatois","year":"2018","unstructured":"Buatois S, Ueckert S, Frey N, Retout S, Mentr\u00e9 F. Comparison of Model Averaging and Model Selection in Dose Finding Trials Analyzed by Nonlinear Mixed Effect Models. AAPS J. 2018;20(3):56.","journal-title":"AAPS J"},{"issue":"1","key":"2626_CR43","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/clpt.1991.5","volume":"49","author":"NC Sambol","year":"1991","unstructured":"Sambol NC, Sheiner LB. Population dose versus response of betaxolol and atenolol: A comparison of potency and variability. Clin Pharmacol Ther. 1991;49(1):24\u201331.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2626_CR44","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1541-0420.2011.01665.x","volume":"68","author":"J Bertrand","year":"2012","unstructured":"Bertrand J, Comets E, Chenel M, Mentr\u00e9 F. Some Alternatives to Asymptotic Tests for the Analysis of Pharmacogenetic Data Using Nonlinear Mixed Effects Models. Biometrics. 2012;68(1):146\u201355.","journal-title":"Biometrics"},{"issue":"1","key":"2626_CR45","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/biom.13583","volume":"79","author":"X Li","year":"2023","unstructured":"Li X, Miao W, Lu F, Zhou XH. Improving Efficiency of Inference in Clinical Trials with External Control Data. Biometrics. 2023;79(1):394\u2013403.","journal-title":"Biometrics"},{"key":"2626_CR46","unstructured":"Mentr\u00e9 F, Leroux R, Seurat J, Fayette L. PFIM: Population Fisher Information Matrix. 2024. Available from: https:\/\/cran.r-project.org\/web\/packages\/PFIM\/index.html. [cited 2025 May 7]."},{"issue":"2","key":"2626_CR47","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.cmpb.2012.05.005","volume":"108","author":"J Nyberg","year":"2012","unstructured":"Nyberg J, Ueckert S, Str\u00f6mberg EA, Hennig S, Karlsson MO, Hooker AC. PopED: An extended, parallelized, nonlinear mixed effects models optimal design tool. Comput Methods Programs Biomed. 2012;108(2):789\u2013805.","journal-title":"Comput Methods Programs Biomed"},{"key":"2626_CR48","doi-asserted-by":"crossref","unstructured":"Bauer RJ, Hooker AC, Mentre F. Tutorial for $DESIGN in NONMEM: Clinical trial evaluation and optimization. CPT: Pharmacometrics & Systems Pharmacology. 2021;10(12):1452\u201365.","DOI":"10.1002\/psp4.12713"}],"container-title":["BMC Medical Research Methodology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-025-02626-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12874-025-02626-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-025-02626-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T07:39:35Z","timestamp":1757317175000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedresmethodol.biomedcentral.com\/articles\/10.1186\/s12874-025-02626-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2626"],"URL":"https:\/\/doi.org\/10.1186\/s12874-025-02626-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.01.30.25321311","asserted-by":"object"}]},"ISSN":["1471-2288"],"issn-type":[{"value":"1471-2288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"12 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For this study, we used a previously published model to simulate data, so no personal data was collected and\/or processed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Synofzik has received consultancy honoraria from Ionis, UCB, Prevail, Orphazyme, Servier, Reata, Biogen, GenOrph, AviadoBio, Biohaven, Zevra, Solaxa, and Lilly, all unrelated to the present manuscript. Dr Emmanuelle Comets has received consultancy honoraria from Sanofi, unrelated to the present manuscript. Drs Hooker and Karlsson have received consultancy fees from and own stock in Pharmetheus, all unrelated to this manuscript. Dr. Mentr\u00e9 has received consultancy fees from Pharmetheus and Ipsen, all unrelated to this manuscript. All other authors declared no competing interests in this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"179"}}